Fierce Biotech Homepage

GSK
Favicon Fierce Biotech

GSK axes key cough drug candidate after phase 3 data disappoint

GSK ended development after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as a key catalyst.
Nick Paul Taylor Jul 17, 2026 5:46am
Takeda booth at AACR 2026
Favicon Fierce Biotech

Takeda’s zasocitinib ‘top-notch’ for hard-to-treat psoriasis

Jul 16, 2026 6:00pm
Jennifer Doudna arriving at the laureates Get together at the Nobel Prize Museum in Stockholm on 6 December 2022
Favicon Fierce Biotech

Nobel Laureate Jennifer Doudna enters AI protein design arena

Jul 16, 2026 2:00pm
chronic kidney disease money
Favicon Fierce Biotech

Dimerix buys Mission’s kidney disease prospect in $292M deal

Jul 17, 2026 5:00am
Leo Cancer Care upright radiotherapy machine

Leo Cancer Care secures $65M for upright radiotherapy

Jul 8, 2026 8:45am
artificial intelligence concept with business analytics

HHS ramps up AI use cases, with most in pre-deployment: BPC

Jun 11, 2026 2:00pm
More News

GHO Capital, CBC Group to form $21B healthcare investment firm

May 20, 2026 12:30pm
Fierce Pharma

FDA's embattled Marty Makary steps down as commissioner

May 12, 2026 2:30pm
Fierce Pharma

Trump plans to end stormy 14-month tenure of FDA chief Makary

May 8, 2026 3:38pm

States' lawsuit against RFK Jr.'s HHS overhaul moves forward

Apr 9, 2026 7:30am